Results 121 to 130 of about 8,764,093 (218)

Patterns of conventional therapy use and advanced therapy initiation drivers in inflammatory bowel disease. [PDF]

Ther Adv Gastroenterol
Raine T, Agboton C, Geddes A, Halmos T, Laharie D, Verstockt B.   +5 more
europepmc   +1 more source

Paclitaxel induces NM2‐dependent cellular contraction through GEF‐H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells

Molecular Oncology, EarlyView.
Taxanes are widely used chemotherapeutics whose effects on cellular mechanics remain poorly understood. We show that paclitaxel induces rapid cellular contraction by promoting GEF‐H1 dissociation from microtubules and non‐muscle myosin II activation through RhoA/ROCK.
Gloria Asensio‐Juárez, Rafael Pérez‐Díaz, Hugo Ramos‐Solano, Marina Garrido‐Casado, Vanessa C. Talayero, Miguel Vicente‐Manzanares   +5 more
wiley   +1 more source

Segmental versus extended colectomy for colonic Crohn's disease in advanced therapy era: a systematic review and Bayesian meta-analysis. [PDF]

Tech Coloproctol
Delgado LM, Pompeu BF, Peñaranda LM, Martins GHA, Viana P, Theis C, de Figueiredo SMP, Formiga FB.   +7 more
europepmc   +1 more source

Bridging the gap: a genetically validated avian chorioallantoic membrane platform for investigation of spontaneous circulating tumor cells

Molecular Oncology, EarlyView.
We established the avian chorioallantoic membrane (CAM) assay as a scalable in vivo model for studying circulating tumor cells (CTCs). Human gastrointestinal tumors spontaneously released genetically validated CTCs that were detected across multiple platforms, demonstrating that the CAM model provides an accessible tool for investigating early cancer ...
Dennis Roth, Rui P. L. Neves, Julia Geheb, Christian Ballmeyer, Nathalie Gaßmann, Kiki C. Andree, Monica Sudarsanam, Christiane Driemel, Celine Örencik, Andrè Franken, Eslam Elmaghraby, Sven H. Loosen, Roderburg Christoph, Sebastian Schoelch, Hans Neubauer, Wolfram T. Knoefel, Nikolas H. Stoecklein, Georg Fluegen   +17 more
wiley   +1 more source

The complex price setting and reimbursement of non-industrial advanced therapy medicinal products. [PDF]

Health Econ Rev
Špacírová Z, Rejon-Parrilla JC, Espín J.   +2 more
europepmc   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU. [PDF]

Front Med (Lausanne)
Van Isterdael C, Mugarza E, Fischer P, Debackere K, Vandenberghe P, Martin Lluesma S, Van Eldere J, Huys I.   +7 more
europepmc   +1 more source

SPHINX31 acts as a SRPK1 inhibitor targeting the ATR/DNA‐PKcs/CHK1 replicative checkpoint to inhibit cell growth in non‐small cell lung cancer

Molecular Oncology, EarlyView.
The kinase SRPK1 directly interacts with the protein TOPBP1 and regulates the pre‐mRNA splicing of WIZ thereby contributing to the activation of the ATR/CHK1 replicative checkpoint in response to replicative stress. This allows cancer cells' genomic stability and survival.
Amani Shreim, Aurelie Genoux, Nadiia Zubchuk, Haoyang Zheng, Perla Salameh, Theo Ziegelmeyer, Fabien Dalonneau, Margot Rouchette, Christiane Oddou, Simona Miron, Helene Polveche, Adiilah Mamode Cassim, Carmen Garrido, Eleni Nikolakaki, Didier Auboeuf, Tao Jia, Sophie Zinn‐Justin, Beatrice Eymin   +17 more
wiley   +1 more source

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study. [PDF]

Am J Ther
Tursi A, Mocci G, Scaldaferri F, Napolitano D, Gaiani F, De' Angelis G, Ribaldone DG, Schillaci E, Savarino EV, Barba CDE, Bendia E, Bolognini L, Balducci D, Quatraccioni C, Martini F, Montori M, Giovanni Maconi, Cataletti G, Massari A, Del Zanna E, Costa F, Ceccarelli L, Gravina AG, Pellegrino R, Bodini G, Pasta A, Marzo M, Miranda A, Cuomo A, Donnarumma L, Lombardi G, Patturelli M, Serio M, Antonella Scarcelli, Pranzo G, Chiara Maria Palmisano, Rocco Spagnuolo, Luzza F, Morano D, Vespere G, Sedda S, Luca LDE, Elisei W, Monterubbianesi R, Di Fonzo M, Fanigliulo L, Pica R, Cassieri C, Cocco A, Stasi E, Grossi L, Bertani L, Cortellini F, Piergallini S, Scarozza P, Bevevino G, Zerboni G, Iacopini F, Rodino' S, Sebkova L, Checchin D, Lamboglia F, Ferrara F, Della Valle N, Colucci R, Bachetti F, Catarella D, D'agostino D, Bartolo EDI, Luppino I, Erboso M, Rocco G, Sacchi C, Zampaletta C, Giacomo Forti, Fiorella S, Bassotti G, Antonelli E, Mucherino C, D'Antonio E, Montesano L, Giovannone M, Vincoli G, Gigliozzi A, D'Ascoli B, Rizzi M, Capone P, Aragona G, Perazzo P, Allegretta L, Tonti P, Neve V, Pagnini C, Grandolfo A, Gatti F, Bucci A, Rizzi M, Picchio M, Onidi FM, Usai Satta P, Papa A.   +100 more
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source